Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot2 - STU 1 ballot
Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot2 - STU 1 ballot
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot2 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
| Page standards status: Informative |
{
"resourceType" : "ArtifactAssessment",
"id" : "179515",
"meta" : {
"versionId" : "20",
"lastUpdated" : "2025-08-14T16:56:33.257Z",
"profile" : [
🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/recommendation-justification"
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Title: </b>Justification for Recommendation: ADA Obesity Management Recommendation 8.17</p><br/><p><b>Justification for Recommendation: </b>Recommendation: ADA Obesity Management Recommendation 8.17</p><br/><table><tr><th>Concept</th><th>Summary</th><th>Rating</th></tr><tr><td>Rating System (coded as: rating-system from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>ADA Level of Evidence</td></tr><tr><td>Direction of Recommendation (coded as: direction-of-recommendation from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>Favors intervention (coded as: RJCS-2021 from https://fevir.net/resources/CodeSystem/27834)</td></tr><tr><td>Ratings (coded as: ratings from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>A</td></tr><tr><td>Recommendation Rating (coded as: recommendation-rating from https://fevir.net/resources/CodeSystem/179423)</td><td>8.17 Metabolic surgery may be considered as an option to treat type 2 diabetes in adults with BMI 30.0–34.9 kg/m2 (27.5–32.4 kg/m2 in Asian Americans) who do not achieve durable weight loss and improvement in comorbidities (including hyperglycemia) with nonsurgical methods. A</td><td>undefined</td></tr><tr><td>Evidence (coded as: evidence from https://fevir.net/resources/CodeSystem/179423)</td><td>ADA Level of Evidence A. A substantial body of evidence has now been accumulated, including data from numerous randomized controlled (nonblinded) clinical trials, demonstrating that metabolic surgery achieves superior glycemic control and reduction of cardiovascular risk factors in patients with type 2 diabetes and obesity compared with various lifestyle/medical interventions.</td><td>undefined</td></tr><tr><td>Summary of Findings (coded as: summary-of-findings from https://fevir.net/resources/CodeSystem/179423)</td><td>ADA Level of Evidence A. A substantial body of evidence has now been accumulated, including data from numerous randomized controlled (nonblinded) clinical trials, demonstrating that metabolic surgery achieves superior glycemic control and reduction of cardiovascular risk factors in patients with type 2 diabetes and obesity compared with various lifestyle/medical interventions.</td><td>undefined</td></tr><tr><td>Discussion (coded as: discussion from https://fevir.net/resources/CodeSystem/179423)</td><td>A substantial body of evidence has now been accumulated, including data from numerous randomized controlled (nonblinded) clinical trials, demonstrating that metabolic surgery achieves superior glycemic control and reduction of cardiovascular risk factors in patients with type 2 diabetes and obesity compared with various lifestyle/medical interventions.<br/>In extended follow-up of obese adults with type 2 diabetes randomized to adding gastric bypass compared with lifestyle and intensive medical management alone, there remained a significantly better composite triple end point in the surgical group at 5 years. However, because the effect size diminished over 5 years, further follow-up is needed to understand the durability of the improvement.</td><td>undefined</td></tr><tr><td>Competing Interests (coded as: competing-interests from https://fevir.net/resources/CodeSystem/179423)</td><td>All members of the PPC are required to disclose potential conflicts of interest with industry and other relevant organizations. These disclosures are discussed at the outset of each Standards of Care revision meeting. Members of the committee, their employers, and their disclosed conflicts of interest are listed in 'Disclosures: Standards of Medical Care in Diabetes—2021' (https://doi.org/10.2337/dc21-SPPC). The ADA funds development of the Standards of Care out of its general revenues and does not use industry support for this purpose. NOTE: The disclosed conflicts of interest was not found at the suggested URL</td><td>undefined</td></tr></table><br/></div>"
},
"extension" : [
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-description",
"valueMarkdown" : "An example using the ArtifactAssessment Resource for representation of the many judgments and concepts used to justify a recommendation."
},
{
"url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status",
"valueCodeableConcept" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type",
"code" : "active",
"display" : "Active"
}
]
}
},
{
"extension" : [
{
"url" : "type",
"valueCode" : "derived-from"
},
{
"url" : "targetReference",
"valueReference" : {
🔗 "reference" : "Citation/32137",
"type" : "Citation",
"display" : "GuidelineCitation: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes (32137)"
}
}
],
"url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/relates-to"
}
],
"identifier" : [
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
"code" : "ACSN",
"display" : "Accession ID"
}
],
"text" : "FEvIR Object Identifier"
},
"system" : "https://fevir.net/FOI",
"value" : "179515",
"assigner" : {
"display" : "Computable Publishing LLC"
}
}
],
"title" : "Justification for Recommendation: ADA Obesity Management Recommendation 8.17",
"citeAs" : "Justification for Recommendation: ADA Obesity Management Recommendation 8.17 [Database Entry: FHIR ArtifactAssessment Resource]. Contributors: In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179515. Revised 2025-08-14. Available at: https://fevir.net/resources/ArtifactAssessment/179515. Computable resource at: https://fevir.net/resources/ArtifactAssessment/179515#json.",
"artifactReference" : {
🔗 "reference" : "Composition/179467",
"type" : "Composition",
"display" : "Recommendation: ADA Obesity Management Recommendation 8.17"
},
"content" : [
{
"type" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "rating-system",
"display" : "Rating System"
}
]
},
"classifier" : [
{
"text" : "ADA Level of Evidence"
}
],
"freeToShare" : true
},
{
"type" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "strength-of-recommendation",
"display" : "Strength of Recommendation"
}
]
},
"freeToShare" : true
},
{
"type" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "direction-of-recommendation",
"display" : "Direction of Recommendation"
}
]
},
"classifier" : [
{
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/27834",
"code" : "RJCS-2021",
"display" : "Favors intervention"
}
]
}
],
"freeToShare" : true
},
{
"type" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "ratings",
"display" : "Ratings"
}
]
},
"classifier" : [
{
"text" : "A"
}
],
"freeToShare" : true
},
{
"summary" : "ADA Level of Evidence A. A substantial body of evidence has now been accumulated, including data from numerous randomized controlled (nonblinded) clinical trials, demonstrating that metabolic surgery achieves superior glycemic control and reduction of cardiovascular risk factors in patients with type 2 diabetes and obesity compared with various lifestyle/medical interventions.",
"type" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "evidence",
"display" : "Evidence"
}
]
},
"relatesTo" : [
{
"type" : "justification",
"targetReference" : {
🔗 "reference" : "Citation/33089",
"type" : "Citation",
"display" : "JournalArticleCitation: Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations"
}
},
{
"type" : "justification",
"targetReference" : {
🔗 "reference" : "Evidence/33244",
"type" : "Evidence",
"display" : "ComparativeEvidence: Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis"
}
}
],
"freeToShare" : true,
"component" : [
{
"summary" : "ADA Level of Evidence A. A substantial body of evidence has now been accumulated, including data from numerous randomized controlled (nonblinded) clinical trials, demonstrating that metabolic surgery achieves superior glycemic control and reduction of cardiovascular risk factors in patients with type 2 diabetes and obesity compared with various lifestyle/medical interventions.",
"type" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "summary-of-findings",
"display" : "Summary of Findings"
}
]
},
"freeToShare" : true
},
{
"type" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "desirable-effects",
"display" : "Desirable Effects"
}
]
},
"freeToShare" : true
},
{
"type" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "undesirable-effects",
"display" : "Undesirable Effects"
}
]
},
"freeToShare" : true
},
{
"summary" : "A substantial body of evidence has now been accumulated, including data from numerous randomized controlled (nonblinded) clinical trials, demonstrating that metabolic surgery achieves superior glycemic control and reduction of cardiovascular risk factors in patients with type 2 diabetes and obesity compared with various lifestyle/medical interventions.<br/>In extended follow-up of obese adults with type 2 diabetes randomized to adding gastric bypass compared with lifestyle and intensive medical management alone, there remained a significantly better composite triple end point in the surgical group at 5 years. However, because the effect size diminished over 5 years, further follow-up is needed to understand the durability of the improvement.",
"type" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "discussion",
"display" : "Discussion"
}
]
},
"relatesTo" : [
{
"type" : "justification",
"targetMarkdown" : "Sjöström\u2008L, Peltonen\u2008M, Jacobson\u2008P, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA\u20082014;311:2297–2304"
},
{
"type" : "justification",
"targetMarkdown" : "Aminian\u2008A, Zajichek\u2008A, Arterburn\u2008DE, et al. Association of metabolic surgery with major adverse cardiovascular outcomes in patients with type 2 diabetes and obesity. JAMA\u20082019;322:1271–1282"
},
{
"type" : "justification",
"targetReference" : {
🔗 "reference" : "Evidence/32144"
}
}
],
"freeToShare" : true
}
]
},
{
"type" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "net-effect",
"display" : "Net Effect"
}
]
},
"freeToShare" : true,
"component" : [
{
"type" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "preferences",
"display" : "Preferences"
}
]
},
"freeToShare" : true
},
{
"type" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "discussion",
"display" : "Discussion"
}
]
},
"freeToShare" : true
}
]
},
{
"type" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "judgments",
"display" : "Judgments"
}
]
},
"freeToShare" : true,
"component" : [
{
"type" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "justification",
"display" : "Justification"
}
]
},
"freeToShare" : true
},
{
"type" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "problem-importance",
"display" : "Problem Importance"
}
]
},
"freeToShare" : true
},
{
"type" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "costs",
"display" : "Costs"
}
]
},
"freeToShare" : true
},
{
"type" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "cost-effectiveness",
"display" : "Cost-effectiveness"
}
]
},
"freeToShare" : true
},
{
"type" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "equity",
"display" : "Equity"
}
]
},
"freeToShare" : true
},
{
"type" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "acceptability",
"display" : "Acceptability"
}
]
},
"freeToShare" : true
},
{
"type" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "feasibility",
"display" : "Feasibility"
}
]
},
"freeToShare" : true
}
]
},
{
"summary" : "All members of the PPC are required to disclose potential conflicts of interest with industry and other relevant organizations. These disclosures are discussed at the outset of each Standards of Care revision meeting. Members of the committee, their employers, and their disclosed conflicts of interest are listed in 'Disclosures: Standards of Medical Care in Diabetes—2021' (https://doi.org/10.2337/dc21-SPPC). The ADA funds development of the Standards of Care out of its general revenues and does not use industry support for this purpose. NOTE: The disclosed conflicts of interest was not found at the suggested URL",
"type" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "competing-interests",
"display" : "Competing Interests"
}
]
},
"freeToShare" : true
}
]
}
IG © 2024+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#1.0.0-ballot2 based on FHIR 6.0.0-ballot3. Generated 2025-09-04
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change